Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Utkarsh Goel; Charalampos Charalampous; Prashant Kapoor; Moritz Binder; Francis K. Buadi; David Dingli; Angela Dispenzieri; Amie Fonder; Morie A. Gertz; Wilson I. Gonsalves; Suzanne R. Hayman; Miriam A. Hobbs; Yi L. Hwa; Taxiarchis Kourelis; Martha Q. Lacy; Nelson Leung; Yi Lin; Rahma M. Warsame; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar

doi:10.1038/s41408-023-00785-y

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M. Warsame, Robert A. Kyle, S. Vincent RajkumarShaji K. Kumar

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	11
Journal	Blood cancer journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00785-y
State	Published - Dec 2023

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-023-00785-y

Cite this

Goel, U., Charalampous, C., Kapoor, P., Binder, M., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Hobbs, M. A., Hwa, Y. L., Kourelis, T., Lacy, M. Q., Leung, N., Lin, Y., Warsame, R. M., Kyle, R. A., ... Kumar, S. K. (2023). Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma. Blood cancer journal, 13(1), Article 11. https://doi.org/10.1038/s41408-023-00785-y

Goel, U, Charalampous, C, Kapoor, P, Binder, M, Buadi, FK, Dingli, D , Dispenzieri, A, Fonder, A, Gertz, MA , Gonsalves, WI, Hayman, SR, Hobbs, MA, Hwa, YL, Kourelis, T , Lacy, MQ, Leung, N, Lin, Y, Warsame, RM, Kyle, RA, Rajkumar, SV & Kumar, SK 2023, 'Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma', Blood cancer journal, vol. 13, no. 1, 11. https://doi.org/10.1038/s41408-023-00785-y

@article{08f0a066fb1a432d9e6e84dbb85fde73,

title = "Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma",

author = "Utkarsh Goel and Charalampos Charalampous and Prashant Kapoor and Moritz Binder and Buadi, {Francis K.} and David Dingli and Angela Dispenzieri and Amie Fonder and Gertz, {Morie A.} and Gonsalves, {Wilson I.} and Hayman, {Suzanne R.} and Hobbs, {Miriam A.} and Hwa, {Yi L.} and Taxiarchis Kourelis and Lacy, {Martha Q.} and Nelson Leung and Yi Lin and Warsame, {Rahma M.} and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.}",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00785-y",

language = "English (US)",

volume = "13",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

AU - Goel, Utkarsh

AU - Charalampous, Charalampos

AU - Kapoor, Prashant

AU - Binder, Moritz

AU - Buadi, Francis K.

AU - Dingli, David

AU - Dispenzieri, Angela

AU - Fonder, Amie

AU - Gertz, Morie A.

AU - Gonsalves, Wilson I.

AU - Hayman, Suzanne R.

AU - Hobbs, Miriam A.

AU - Hwa, Yi L.

AU - Kourelis, Taxiarchis

AU - Lacy, Martha Q.

AU - Leung, Nelson

AU - Lin, Yi

AU - Warsame, Rahma M.

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

PY - 2023/12

Y1 - 2023/12

UR - http://www.scopus.com/inward/record.url?scp=85146128565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146128565&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00785-y

DO - 10.1038/s41408-023-00785-y

M3 - Letter

C2 - 36631454

AN - SCOPUS:85146128565

SN - 2044-5385

VL - 13

JO - Blood cancer journal

JF - Blood cancer journal

IS - 1

M1 - 11

ER -

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this